Company attributes
Other attributes
Genocea is a biopharmaceutical company headquartered in Cambridge, Massachusetts that was founded by Lux and spun-out from Harvard Medical School in 2006.
Genocea has a proprietary technology platform, ATLAS, which mimics the human immune system. The system is used find targets for adoptive cell therapies like chimeric antigen receptor (CAR-Ts) where a patient’s T cells are engineered to attack certain tumor cells.
ATLAS uses human immune cells to identify relevant antigens from libraries of pathogen proteins. Hundreds of human T cells are tested with thousands of potential antigens. The platform is used to identify targets most likely to illicit an immune response.
Genocea’s pipeline includes clinical-stage T cell-enabled product candidates such as GEN-003 for genital herpes, GEN-004 for pneumococcus and earlier stage programs in chlamydia, malaria and cancer immunotherapy.Genocea has a cancer vaccine candidate, GEN-009, which is in a Phase1/2a clinical trial as of January 2019 with estimated completion in 2022.
Genocea has been partnered with Richard Malley, MD, at Boston Children’s Hospital since 2008. Together they are working on a vaccine for pneumococcal infections such as pneumonia and meningitis.ATLAS was developed by Dr. Darren Higgins at Harvard University.
